Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EXAGEN INC.XGN · Entity 935 | Director | June 09, 2026 | August 19, 2026 |
| Fulgent Genetics, Inc.FLGT · Entity 2545 | CFO and Treasurer | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EXAGEN INC.
Report date June 09, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option(right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.31 · Expires 2036-06-08 | Direct | 46,500 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 37,500 · Balance 46,500 F1: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
Fulgent Genetics, Inc.
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 356,543 |
Reported balance
After 2026-09-01 transaction · row 1
1 source rowRow 1 · 2026-09-01 · Tax withholding · Disposed 2,087 · Balance 356,543 F1: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 25, 2025, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2024 Filed Aug 6, 2024 20:12 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,412 | $25.06 | $35,384.72 |
DisclosureSEC source: 0000950170-24-091816 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,888 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 3, 2020, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2020. Read SEC document |
| July 26, 2024 Filed Jul 30, 2024 20:28 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 2,738 | $23.66 | $64,781.08 |
DisclosureSEC source: 0000950170-24-087891 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,300 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on November 7, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 20:06 UTC | EXAGEN INC. XGN · Entity 935 | GrantStock Option(right to buy) · Derivative | 9,000 | $0.00 Strike: $1.99 | $0.00 |
DisclosureSEC source: 0001274737-24-000062 · wk-form4_1718222776.xml · derivative · entry 1 Kim Paul · CIK 0001253820 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2034-06-09 F1 · derivative.exercise_date: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. Read SEC document |
| June 01, 2024 Filed Jun 4, 2024 20:56 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 424 | $20.65 | $8,755.60 |
DisclosureSEC source: 0000950170-24-068793 · ownership.xml · nonDerivative · entry 2 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,038 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. Read SEC document |
| June 01, 2024 Filed Jun 4, 2024 20:56 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,129 | $20.65 | $23,313.85 |
DisclosureSEC source: 0000950170-24-068793 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,462 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. Read SEC document |
| May 23, 2024 Filed May 28, 2024 20:22 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 669 | $21.14 | $14,142.66 |
DisclosureSEC source: 0000950170-24-065239 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,591 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023. Read SEC document |
| May 03, 2024 Filed May 7, 2024 20:21 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,412 | $21.50 | $30,358.00 |
DisclosureSEC source: 0000950170-24-054557 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 218,260 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 3, 2020, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2020. Read SEC document |
| April 26, 2024 Filed Apr 30, 2024 20:03 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 2,738 | $20.10 | $55,033.80 |
DisclosureSEC source: 0000950170-24-050512 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 219,672 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on November 7, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:27 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 424 | $23.24 | $9,853.76 |
DisclosureSEC source: 0000950170-24-026007 · ownership.xml · nonDerivative · entry 2 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,410 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:27 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,129 | $23.24 | $26,237.96 |
DisclosureSEC source: 0000950170-24-026007 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,834 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. Read SEC document |
| February 26, 2024 Filed Feb 29, 2024 00:11 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 24,732 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-022465 · ownership.xml · nonDerivative · entry 5 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 223,963 F5 · shares: Restricted stock units. The shares subject to the restricted stock units vest over a period of three years, with 1/3rd of such shares vesting 12 months after February 26, 2024, and 1/12th of such shares vesting at the end of every three month period thereafter over the remaining 24 months, subject to continued service for Issuer on each vesting date. Read SEC document |
| February 26, 2024 Filed Feb 29, 2024 00:11 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 3,502 | $24.26 | $84,958.52 |
DisclosureSEC source: 0000950170-24-022465 · ownership.xml · nonDerivative · entry 4 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,231 F4 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 23, 2023. Read SEC document |
| February 26, 2024 Filed Feb 29, 2024 00:11 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 2,217 | $24.26 | $53,784.42 |
DisclosureSEC source: 0000950170-24-022465 · ownership.xml · nonDerivative · entry 3 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,733 F3 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 28, 2022. Read SEC document |
| February 26, 2024 Filed Feb 29, 2024 00:11 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 6,203 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-022465 · ownership.xml · nonDerivative · entry 2 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,950 F2 · shares: Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 23, 2023. Read SEC document |
| February 26, 2024 Filed Feb 29, 2024 00:11 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 3,927 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-022465 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,747 F1 · shares: Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 28, 2022. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 23:55 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 2,670 | $24.06 | $64,240.20 |
DisclosureSEC source: 0000950170-24-021522 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,820 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 23, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 27, 2023. Read SEC document |
| February 03, 2024 Filed Feb 7, 2024 00:27 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 982 | $24.65 | $24,206.30 |
DisclosureSEC source: 0000950170-24-011858 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,490 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 3, 2020, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2020. Read SEC document |
| January 26, 2024 Filed Jan 30, 2024 21:21 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,988 | $25.60 | $50,892.80 |
DisclosureSEC source: 0000950170-24-008855 · ownership.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,472 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on November 7, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
| December 04, 2023 Filed Dec 6, 2023 22:54 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,437 | $27.57 | $39,622.69 |
DisclosureSEC source: 0001209191-23-057666 · doc4.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,460 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. F2 · price: The shares were sold in multiple transactions at prices ranging from $27.25 to $27.79, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 16, 2023 Filed Nov 20, 2023 21:27 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,307 | $27.25 | $35,617.19 |
DisclosureSEC source: 0001209191-23-056060 · doc4.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 201,897 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on November 1, 2019, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 5, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $27.02 to $27.54, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 03, 2023 Filed Nov 7, 2023 22:09 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,240 | $26.94 | $33,405.60 |
DisclosureSEC source: 0001209191-23-054620 · doc4.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,204 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 3, 2020, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2020. Read SEC document |
| October 26, 2023 Filed Oct 30, 2023 21:25 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 9,617 | $24.03 | $231,048.43 |
DisclosureSEC source: 0001209191-23-053872 · doc4.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,444 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units held by the reporting person and assumed by the Issuer on November 7, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022. Read SEC document |
| September 07, 2023 Filed Sep 11, 2023 20:35 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,492 | $31.41 | $46,860.59 |
DisclosureSEC source: 0001209191-23-048932 · doc4.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,061 F1 · shares: The shares were sold from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. F2 · price: The shares were sold in multiple transactions at prices ranging from $31.345 to $31.56, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 28, 2023 Filed Aug 30, 2023 20:54 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 10,299 | $33.62 | $346,296.67 |
DisclosureSEC source: 0001209191-23-047749 · doc4.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,553 F1 · price: The shares were sold in multiple transactions at prices ranging from $33.51 to $33.90, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 17, 2023 Filed Aug 21, 2023 20:40 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,307 | $33.88 | $44,282.60 |
DisclosureSEC source: 0001209191-23-046715 · doc4.xml · nonDerivative · entry 2 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,852 F3 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on November 1, 2019, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 5, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $33.55 to $34.19, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 17, 2023 Filed Aug 21, 2023 20:40 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 491 | $33.88 | $16,635.62 |
DisclosureSEC source: 0001209191-23-046715 · doc4.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 227,159 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $33.55 to $34.19, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 03, 2023 Filed Aug 7, 2023 21:34 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,240 | $40.08 | $49,699.20 |
DisclosureSEC source: 0001209191-23-044857 · doc4.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 227,650 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 3, 2020, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2020. Read SEC document |
| July 24, 2023 Filed Jul 26, 2023 20:06 UTC | EXAGEN INC. XGN · Entity 935 | GrantStock Option(right to buy) · Derivative | 15,000 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001274737-23-000080 · wk-form4_1690401966.xml · derivative · entry 1 Kim Paul · CIK 0001253820 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-07-23 F1 · derivative.exercise_date: The option is exercisable as it vests. The total number of shares of common stock subject to the option vests in 36 equal monthly installments over the three-year period beginning on August 24, 2023, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| June 02, 2023 Filed Jun 6, 2023 21:09 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,403 | $40.30 | $56,535.43 |
DisclosureSEC source: 0001209191-23-034797 · doc4.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 228,890 F1 · shares: The shares were sold from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. F2 · price: The shares were sold in multiple transactions at prices ranging from $39.79 to $40.75, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:19 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 345 | $35.46 | $12,234.49 |
DisclosureSEC source: 0001209191-23-030998 · doc4.xml · nonDerivative · entry 2 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,293 F3 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $34.96 to $36.15, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:19 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 921 | $35.46 | $32,660.78 |
DisclosureSEC source: 0001209191-23-030998 · doc4.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,638 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on November 1, 2019, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 5, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $34.96 to $36.15, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 03, 2023 Filed May 5, 2023 21:02 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 865 | $29.33 | $25,370.45 |
DisclosureSEC source: 0001209191-23-027768 · doc4.xml · nonDerivative · entry 1 Kim Paul · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 231,559 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 3, 2020, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2020. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:32 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 3,805 | $31.85 | $121,189.25 |
DisclosureSEC source: 0001209191-23-015542 · doc4.xml · nonDerivative · entry 2 KIM PAUL · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 232,424 F2 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 28, 2022, which grants were originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 2, 2022. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:32 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 433 | $31.85 | $13,791.05 |
DisclosureSEC source: 0001209191-23-015542 · doc4.xml · nonDerivative · entry 1 KIM PAUL · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,229 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 27, 2019, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 4, 2019. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 22:21 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 741 | $31.65 | $23,452.65 |
DisclosureSEC source: 0001209191-23-013290 · doc4.xml · nonDerivative · entry 3 KIM PAUL · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,662 F3 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of the above performance-based restricted stock units granted to the reporting person on February 28, 2022. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 22:21 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 14,218 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-013290 · doc4.xml · nonDerivative · entry 2 KIM PAUL · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,403 F2 · shares: Restricted stock units. The shares subject to the restricted stock units vest over a period of three years, with 1/3rd of such shares vesting 12 months after February 23, 2023, and 1/12th of such shares vesting at the end of every three month period thereafter over the remaining 24 months, subject to continued service for Issuer on each vesting date. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 22:21 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 2,142 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-013290 · doc4.xml · nonDerivative · entry 1 KIM PAUL · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,185 F1 · shares: Performance-based restricted stock units. The shares vested pursuant to certain performance milestones for performance-based restricted stock units granted on February 28, 2022. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:04 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,019 | $33.99 | $34,635.81 |
DisclosureSEC source: 0001209191-23-010744 · doc4.xml · nonDerivative · entry 2 KIM PAUL · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,043 F2 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on November 1, 2019, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 5, 2019. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 22:04 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 321 | $33.99 | $10,910.79 |
DisclosureSEC source: 0001209191-23-010744 · doc4.xml · nonDerivative · entry 1 KIM PAUL · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,062 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2019. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 22:17 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,020 | $36.21 | $36,934.20 |
DisclosureSEC source: 0001209191-23-007605 · doc4.xml · nonDerivative · entry 1 KIM PAUL · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,383 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 3, 2020, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2020. Read SEC document |
| December 02, 2022 Filed Dec 6, 2022 21:42 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 653 | $35.33 | $23,069.71 |
DisclosureSEC source: 0001209191-22-060015 · doc4.xml · nonDerivative · entry 1 KIM PAUL · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,403 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 27, 2019, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on March 4, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $34.86 to $35.98, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 21:13 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 490 | $35.89 | $17,586.39 |
DisclosureSEC source: 0001209191-22-057841 · doc4.xml · nonDerivative · entry 2 KIM PAUL · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,056 F3 · shares: The shares were sold from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $35.515 to $36.370, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 16, 2022 Filed Nov 18, 2022 21:13 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,306 | $35.89 | $46,873.12 |
DisclosureSEC source: 0001209191-22-057841 · doc4.xml · nonDerivative · entry 1 KIM PAUL · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,546 F1 · shares: The shares were sold from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on November 1, 2019, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 5, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $35.515 to $36.370, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| November 07, 2022 Filed Nov 10, 2022 02:07 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 77,585 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-056319 · doc4.xml · nonDerivative · entry 1 KIM PAUL · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,852 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of November 7, 2022 (the "Merger Agreement") by and among Fulgent Genetics, Inc. ("Fulgent Genetics"), FG Merger Sub, Inc. ("FG"), Fulgent Pharma Holdings, Inc. ("Fulgent Pharma"), and the stockholders listed therein, FG merged with and into Fulgent Pharma (the "Merger"), with Fulgent Pharma being the surviving corporation following the Merger. At the effective time of the Merger (the "Effective Time"), each award of restricted stock units ("RSUs") based on Fulgent Pharma common stock that was outstanding immediately prior to the Effective Time ("Fulgent Pharma RSUs") was assumed and converted into the right to receive RSUs based on the common stock of Fulgent Genetics with the same terms and conditions as the Fulgent Pharma RSUs immediately prior to the Effective Time, subject to the applicable exchange ratio. F2 · kind: (continued from footnote 1) Twenty-five percent (25%) of the shares subject to RSUs reported herein will vest on the first anniversary of the date of the award, October 26, 2022, and 1/16th of the shares will vest every three months over the remaining 36-month period, subject to continued service for Issuer on each vesting date. Read SEC document |
| November 03, 2022 Filed Nov 7, 2022 22:06 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,240 | $37.89 | $46,983.60 |
DisclosureSEC source: 0001209191-22-055970 · doc4.xml · nonDerivative · entry 1 KIM PAUL · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,267 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 3, 2020, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on August 5, 2020. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 21:03 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 662 | $41.39 | $27,402.96 |
DisclosureSEC source: 0001209191-22-049195 · doc4.xml · nonDerivative · entry 1 KIM PAUL · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,507 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 27, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $41.09 to $41.90, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 21:05 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 1,945 | $48.89 | $95,099.80 |
DisclosureSEC source: 0001209191-22-046867 · doc4.xml · nonDerivative · entry 1 KIM PAUL · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,169 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 1, 2019 and November 1, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $48.67 to $49.02, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:11 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | Tax withholdingCommon Stock | 1,048 | $62.93 | $65,950.64 |
DisclosureSEC source: 0001209191-22-044564 · doc4.xml · nonDerivative · entry 1 KIM PAUL · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,114 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on August 3, 2020. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 20:16 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 415 | $55.10 | $22,867.33 |
DisclosureSEC source: 0001209191-22-034511 · doc4.xml · nonDerivative · entry 1 KIM PAUL · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,162 F1 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 27, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $54.98 to $55.27, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:41 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | SaleCommon Stock | 866 | $53.38 | $46,229.07 |
DisclosureSEC source: 0001209191-22-030070 · doc4.xml · nonDerivative · entry 2 KIM PAUL · CIK 0001253820 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,577 F3 · shares: The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on November 1, 2019. F2 · price: The shares were sold in multiple transactions at prices ranging from $53.27 to $53.57, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.